T helper 1 (Th1) lymphocyte proliferation pathway (Th1 proliferation pathway)

The T helper 1 (Th1) lymphocyte proliferation pathway is a complex biological process responsible for the expansion of Th1 cells, which are critical for cell-mediated immunity and defense against intracellular pathogens (PubMed: 21730165). This pathway is primarily initiated by Interleukin-12 (IL-12) and Interferon-gamma (IFN-γ), which signal through the JAK-STAT pathway to activate the master transcription factor T-bet (TBX21) (PubMed: 10529608, PubMed: 10761931). T-bet coordinates the expression of Th1-specific genes, including IFN-γ itself, creating a positive feedback loop that drives Th1 dominance and suppresses alternative T-cell lineages (PubMed: 10761931). While essential for clearing infections, dysregulation of this pathway leads to excessive inflammation and is a major driver of autoimmune diseases such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis (PubMed: 23585034). Therapeutic interventions often target specific nodes within this pathway, such as the IL-12/23 p40 subunit or Janus kinases, to suppress the pathological immune response (FDA Label). However, because these pathways are also vital for normal immune surveillance, their pharmacological inhibition is associated with significant safety concerns, including an increased risk of opportunistic infections and potential long-term risks of malignancy (FDA Label).

Other names

Th1 cell proliferationType 1 T helper cell expansionTh1 signaling pathwayT-helper 1 cell differentiation pathway

Drugs modulating this pathway function by inhibiting key signaling nodes, such as the IL-12/IL-23 cytokine axis (e.g., ustekinumab), Janus kinases (e.g., tofacitinib), or the calcineurin-NFAT signaling cascade (e.g., cyclosporine), thereby preventing the activation, differentiation, and clonal expansion of Th1 cells (PubMed: 23585034; FDA Label).